<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03924466</url>
  </required_header>
  <id_info>
    <org_study_id>UZBRU_VHH1_3</org_study_id>
    <secondary_id>2016-002164-13</secondary_id>
    <nct_id>NCT03924466</nct_id>
  </id_info>
  <brief_title>Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients</brief_title>
  <acronym>VUBAR</acronym>
  <official_title>Quantification of 68-GaNOTA-Anti-HER2 VHH1 Uptake in Metastasis of Breast Carcinoma Patients and Assessment of Repeatability (VUBAR) - Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kom Op Tegen Kanker</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Agentschap voor Innovatie door Wetenschap en Technologie, Project Toegepast Biomedisch onderzoek met een primair Maatschappelijke finaliteit.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study objective: To quantify the uptake of 68GaNOTA-Anti-HER2 VHH1 in local or distant&#xD;
      metastases from breast carcinoma patients and to assess repeatability of the image-based HER2&#xD;
      quantification. The uptake will be correlated to results obtained via biopsy of the same&#xD;
      lesion, if available. Time schedule: After inclusion, patients will be injected intravenously&#xD;
      with 37 - 185 MBq 68GaNOTA-Anti-HER2 VHH1 with a total mass of up to 200 Î¼g NOTA-Anti-HER2&#xD;
      VHH1. Serum and plasma samples will be collected at injection. At 90 min after injection, a&#xD;
      total body PET/CT scan will be performed. Patients will undergo a second PET/CT procedure,&#xD;
      identical to the first procedure, within 8 days, with a minimal interval of 18h. Based on&#xD;
      PET/CT images, up to 2 lesions will be selected for optional image-guided biopsy. Biopsy will&#xD;
      be performed max. 28 days after the second PET/CT. Plasma and serum samples will be obtained&#xD;
      between 60 and 365 days after first injection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Repeatability of lesional PET/CT characteristics</measure>
    <time_frame>90 min post injection</time_frame>
    <description>The lesional tracer uptake in local and distant metastases of at least 12 mm (for lymph nodes short axis) will be measured on both PET/CT's (expressed as standard uptake value (SUV) and repeatability will be calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Within-patient tumor heterogeneity for HER2 expression using PET/CT imaging</measure>
    <time_frame>90 min post injection</time_frame>
    <description>Within-patient tumor heterogeneity for HER2 expression, observed on 68GaNOTA-Anti-HER2 VHH1 PET/CT or biopsy analyses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>prior to and between 60 and 365 days after the first injection</time_frame>
    <description>Immunogenicity assessed on plasma samples obtained prior to injection of the IMP and obtained between 60 and 365 days after the (first) injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histopathological results of biopsied lesions and correlation with PET/CT results</measure>
    <time_frame>max 28 days after the second PET/CT</time_frame>
    <description>semi-quantitative score of HER2 expression using immunohistochemistry performed on biopsied/resected tissues if available</description>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Metastatic Breast Carcinoma</condition>
  <condition>Locally Advanced Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>68GaNOTA-Anti-HER2 VHH1</intervention_name>
    <description>Injection of the radiopharmaceutical and PET/CT 90 min post injection</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients will only be included in the study if they meet all of the following criteria:&#xD;
&#xD;
          -  Patient who has given informed consent&#xD;
&#xD;
          -  Patient with age 18 years or older&#xD;
&#xD;
          -  Patient with locally or distantly advanced breast carcinoma, with at least 1 lesion of&#xD;
             at least 12 mm maximal diameter. For lymph node metastases, the largest diameter&#xD;
             should be at least 15 mm and the short axis at least 12 mm.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients will not be included in the study if one or more of the following criteria&#xD;
        applies:&#xD;
&#xD;
          -  Patient is pregnant&#xD;
&#xD;
          -  Patient is breast feeding&#xD;
&#xD;
          -  Patient with recent (&lt; 1 week) gastrointestinal disorders with diarrhea as major&#xD;
             symptom&#xD;
&#xD;
          -  Patient with any serious active infection&#xD;
&#xD;
          -  Patient who has any other life-threatening illness or organ system dysfunction, which&#xD;
             in the opinion of the investigator would either compromise patient safety or interfere&#xD;
             with the evaluation of the test radiopharmaceutical&#xD;
&#xD;
          -  Patient who cannot communicate reliably with the investigator&#xD;
&#xD;
          -  Patient who is unlikely to cooperate with the requirements of the study&#xD;
&#xD;
          -  Patient who is unwilling and/or unable to give informed consent&#xD;
&#xD;
          -  Patient at increased risk of death from a pre-existing concurrent illness&#xD;
&#xD;
          -  Patient who participated already in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marleen KEYAERTS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitair Ziekenhuis Brussel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>UZ Brussel</last_name>
    <phone>+3224776013</phone>
    <email>afspraak_nucleaire@uzbrussel.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Uz Brussel</name>
      <address>
        <city>Brussels</city>
        <state>Brussel</state>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>UZ BRUSSEL</last_name>
      <phone>3224776013</phone>
      <email>afspraak_nucleaire@uzbrussel.be</email>
    </contact>
    <investigator>
      <last_name>MARLEEN KEYAERTS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 18, 2019</study_first_submitted>
  <study_first_submitted_qc>April 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2019</study_first_posted>
  <last_update_submitted>October 22, 2020</last_update_submitted>
  <last_update_submitted_qc>October 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HER2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

